Dulaglutide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack summarizes published evidence, dosing context, safety considerations, and Australian legal status for Dulaglutide.

What the sources say

In REWIND, a cardiovascular-outcomes trial with median follow-up of 5.4 years, major adverse cardiovascular events occurred in 12.0% of participants assigned dulaglutide and 13.4% assigned placebo (hazard ratio 0.88, 95% CI 0.79–0.99). This supports benefit in the studied type 2 diabetes population, not a universal preventive claim. (Human clinical trials; Gerstein et al., "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)", 2019-06-09)
Patient posts in a Trulicity forum thread describe varied experiences, including nausea or reflux and reports of improved glucose or weight; these are unverified accounts and cannot establish efficacy, frequency or causation. (Community reports; Diabetes.co.uk Forum, "Reactions to Trulicity", 2020-03-13)
Dulaglutide is a GLP-1 receptor agonist used to improve glycaemic control in type 2 diabetes; the Australian Trulicity label describes the specific product and use. (Educator material (not peer reviewed); TGA, Australian Public Assessment Report attachment: Product Information for dulaglutide (Trulicity), 2015-07-27)
The TGA states that the evidence available was insufficient to support a causal association between GLP-1 receptor agonists and suicidal or self-harming behaviours, but product warnings were harmonised and health professionals are advised to monitor for new or worsening depression, suicidal thoughts or unusual behavioural changes. (Educator material (not peer reviewed); TGA, "GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours", 2025-12-01)
The older Australian product-information copy describes gastrointestinal adverse effects and product-specific cautions, including pancreatitis and gallbladder concerns. Refer to the current Trulicity PI for current warnings and risk language. (Educator material (not peer reviewed); TGA, Australian Public Assessment Report attachment: Product Information for dulaglutide (Trulicity), 2015-07-27)
The June 2026 Poisons Standard defines Schedule 4 medicines as prescription-only; this legal classification does not establish current stock or PBS eligibility. (Educator material (not peer reviewed); Australian Government, Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, 2026-05-28)

Sources

Dosing, stacking and protocol details are not published here.